40.24

5.73% 2.18

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $40.24, with a volume of 512.72K. It is up +5.73% in the last 24 hours and up +8.43% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$38.06

Open:

$38.76

24h Volume:

512.72K

Relative Volume:

1.01

Market Cap:

$725.88M

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-4.3882

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

+11.78%

1M Performance:

+8.43%

6M Performance:

-41.11%

1Y Performance:

-25.70%

1-Day Range:

$38.21

$40.84

1-Week Range:

$35.34

$40.84

52-Week Range:

$26.70

$91.83

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	40.24	725.88M	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

May 02, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PRAX Stock News - GuruFocus

May 02, 2025

Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 02, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 02, 2025

Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan

May 02, 2025

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - Yahoo Finance

May 02, 2025

Wells Fargo & Company MN Boosts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World

May 02, 2025

May 01, 2025

Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts - Benzinga

May 01, 2025

PRAX: HC Wainwright Reiterates Buy Rating and $105 Price Target | PRAX Stock News - GuruFocus

May 01, 2025